Nancy J Olsen
Nancy J Olsen
The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as...
Is denosumab better than alendronate in the treatment of osteoporosis? [0.03%]
-denosumab治疗骨质疏松优于阿伦磷酸盐吗？
E Michael Lewiecki
E Michael Lewiecki
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand (RANKL), the principal mediator of osteoclastic bone resorption. By binding to RANKL, denosumab reduces the differentiation, activity and s...
Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares? [0.03%]
糖皮质激素治疗痛风发作是否与非甾体抗炎药相当？
Angelo L Gaffo,Kenneth G Saag
Angelo L Gaffo
Frank Buttgereit,Gerd-Rüdiger Burmester,Brian J Lipworth
Frank Buttgereit
David L Scott,Sophia Steer
David L Scott
Activated B cells in autoimmune diseases: the case for a regulatory role [0.03%]
自身免疫性疾病中的活化B细胞及其调节作用的证据
Stephen M Anderton,Simon Fillatreau
Stephen M Anderton
B lymphocytes contribute to immunity through organogenesis of secondary lymphoid organs, presentation of antigen to T cells, production of antibodies, and secretion of cytokines. Their roles in autoimmune diseases are complex. Clinical tria...
Jakko van Ingen,Martin J Boeree,P N Richard Dekhuijzen et al.
Jakko van Ingen et al.
This Review focuses on the emergence of mycobacterial disease in patients undergoing treatment for rheumatic disease with four new drug classes--tumor necrosis factor (TNF) inhibitors, human interleukin (IL)-1 receptor antagonists, anti-CD2...
Issues in the design of new clinical trials for rheumatoid arthritis therapeutics [0.03%]
新的临床试验在治疗类风湿性关节炎的设计中遇到的问题
William D Schwieterman
William D Schwieterman
Rheumatoid arthritis (RA) is a chronic, heterogeneous disease, for which there has traditionally been few reliable prognostic indicators or simple clinical outcome measures with which to adequately assess disease status or clinical improvem...
Peter E Lipsky
Peter E Lipsky